Abstracts tagged "spondyloarthritis"

Abstract Number: 2364 • ACR Convergence 2024
Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
Marina Magrey¹, Denis Poddubnyy², Mark Lebwohl³, Rajan Bajracharya⁴, Dirk de Cuyper⁵, Alexander Marten⁶, Luke Peterson⁷, Jeffrey L. Stark⁸ and Joseph F. Merola⁹, ¹Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ²Charite-Universitatsmedizin Berlin, Berlin, Germany, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Morrisville, NC, ⁸UCB Pharma, Smyrna, GA, ⁹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Anxiety and depression are highly prevalent in patients (pts) with axial spondyloarthritis (axSpA)/PsA.1,2 We report mental health data in pts with axSpA/PsA from trials…
Abstract Number: 0370 • ACR Convergence 2023
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
Melissa Oliver¹, Kelly Mosesso², Pamela F. Weiss³, Robert Colbert⁴, Matthew Stoll⁵ and Hemalatha Srinivasalu⁶, ¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴NIH/NIAMS, Bethesda, MD, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Children's National Hospital, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…
Abstract Number: 0523 • ACR Convergence 2023
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Fabian Proft¹, Désirée van der Heijde², Xenofon Baraliakos³, Joerg Ermann⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Vanessa Taieb⁸, Astrid van Tubergen⁹ and Victoria Navarro-Compán¹⁰, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Colombes, France, ⁹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ¹⁰Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease which requires optimal management and disease control. Patients (pts) can experience loss of response in the…
Abstract Number: 0841 • ACR Convergence 2023
Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis
Maureen Dubreuil¹, Abhijeet Danve², Swetha Ann Alexander³, Mohamad Bittar⁴, Liana Fraenkel⁵, Alyssa Grimshaw⁶, Anand Kumthekar⁷, Michael LaValley⁸, Jean liew⁹, Marina Nighat Magrey¹⁰, Vikas Majithia¹¹, Sali Merjanah¹², Hillary Norton¹³, Jessica A Walsh¹⁴ and Atul Deodhar¹⁵, ¹Department of Rheumatology, Boston University School of Medicine, Milton, MA, ²Yale University School of Medicine, Glastonbury, CT, ³University of Utah Health, Salt Lake City, UT, ⁴The University of Tennessee Health Science Center, Memphis, TN, ⁵Berkshire Health Systems, Lenox, MA, ⁶Yale University, New Haven, CT, ⁷Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁸Boston University School of Public Health, Arlington, MA, ⁹Boston University, Boston, MA, ¹⁰Case Western Reserve University, University Hospitals, Cleveland, OH, ¹¹Mayo Clinic Florida, Jacksonville, FL, ¹²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ¹³Inspire Santa Fe Rheumatology, Santa Fe, NM, ¹⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ¹⁵Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: In the United States (US), the diagnosis of axial spondyloarthritis (axSpA) continues to be delayed by an average of 10 years from symptom onset.…
Abstract Number: 1391 • ACR Convergence 2023
Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Franziska Neinert¹, Imke Redeker², Styliani Tsiami¹, David Kiefer¹, Barbara Guminski¹, Xenofon Baraliakos³, Juergen Braun¹ and Uta Kiltz⁴, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²Ruhr Universität Bochum, Bochum, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Achieving remission is the treatment target for patients (pts.) with axial spondyloarthritis (axSpA).Remission rates over longer periods in a real-life setting have not been…
Abstract Number: 1644 • ACR Convergence 2023
The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients
Alba Boix-Amorós¹, Rebecca Blank², Adam Cantor¹, Jesus Sanz³, Ana Gutiérrez-Casbas⁴, Jordi Gratacos Masmitja⁵, Iago Rodríguez -Lago⁶, Elisa Trujillo⁷, Ignacio Marin-Jimenez⁸, Zulema Plaza⁹, Marta Domínguez¹⁰, Jose Federico Diaz-Gonzalez¹¹, Juan D Canete¹², Jose Scher¹³ and Jose Clemente¹, ¹Icahn School of Medicine, New York, NY, ²New York University, New York, NY, ³Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital General Universitario Dr. Balmis, Alicante, Spain, ⁵University Hospital Parc Taulí, Sabadell, Spain, ⁶Gastroenterology department Hospital Galdakao, Galdakao, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Public Health System, Madrid, Spain, ⁹Universidad Autónoma de Madrid, Madrid, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Universitario de Canarias, La Laguna, Spain, ¹²Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹³New York University School of Medicine, New York, NY
Background/Purpose: Nearly 8% of patients with spondyloarthritis (SpA) manifest symptoms that are compatible with active inflammatory bowel disease (IBD), despite not having any previous diagnosis…
Abstract Number: 1886 • ACR Convergence 2023
Costotransverse Joint Ankylosis and Association with Syndesmophyte Progression in Patients with Radiographic Axial Spondyloarthritis
Hong Ki Min¹, Se Hee Kim², Hae-Rim Kim³, Sang-Heon Lee¹ and Sang-Hoon Lee², ¹Konkuk University School of Medicine, Seoul, South Korea, ²Kyung Hee University Hospital at Gangdong, Seoul, South Korea, ³Rheumatology, Konkuk University Medical Center, Seoul, South Korea
Background/Purpose: Costotransverse joint ankylosis in radiographic axial spondyloarthritis (r-axSpA) patients was measured. Furthermore, the association between syndesmophyte progression assessed by CT syndesmophyte score (CTSS) and…
Abstract Number: 2207 • ACR Convergence 2023
Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States
William Odell¹, Swetha Ann Alexander², Nicolas Page³, Narinder Maheshwari⁴ and Abhijeet Danve⁵, ¹Yale University, Wethersfield, CT, ²University of Utah Health, Salt Lake City, UT, ³Yale University, New Haven, CT, ⁴UCONN Health, Farmington, CT, ⁵Yale University School of Medicine, Glastonbury, CT
Background/Purpose: Inflammatory back pain (IBP) is the defining feature of axial spondyloarthritis (axSpA). However, it may be difficult for non-rheumatology physicians (non-rheums) to distinguish between…
Abstract Number: 2225 • ACR Convergence 2023
Long-term Evolution of Spondyloarthritis Patients Included in REGISPONSER, 17 Years Later (REGISPON-3 Study)
María Ángeles Puche Larrubia¹, Lourdes Ladehesa Pineda², María del carmen Ábalos Aguilera³, Desiree Ruiz Vilchez⁴, Laura Berbel Arcobé⁵, Xavier Juanola Roura⁶, Marta Arévalo Salaet⁷, Mireia Moreno⁸, Raquel Almodóvar González⁹, Cristina Pijoan Moratalla⁹, Marta Valero Expósito¹⁰, Verónica García García¹⁰, Beatriz Joven Ibáñez¹¹, Manuel José Moreno Ramos¹², Enrique Tomás Ornilla Laraudogoitia¹³, Alejandro Escudero Contreras¹⁴, Eduardo Collantes Estévez¹⁵ and Clementina López Medina¹⁶, ¹Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁵H.U. Bellvitge, Barcelona, Spain, ⁶Hospital Universitari de Bellvitge, Barcelona, Spain, ⁷Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ⁸Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ⁹Alcorcón Foundation University Hospital, Madrid, Spain, ¹⁰Ramón y Cajal University Hospital, Madrid, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Rheumatology Department Hospital Virgen de la Arrixaca, El Palmar Murcia, Spain, ¹³University Hospital of Navarra, Navarra, Spain, ¹⁴Reina Sofia University Hospital, Córdoba, Spain, ¹⁵Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹⁶Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain
Background/Purpose: The cross-sectional REGISPONSER study was conducted in 2004 in 31 centers from Spain, including a total of 2367 patients who met the European Spondyloarthropathy…
Abstract Number: 0372 • ACR Convergence 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
Hermine Brunner¹, Ivan Foeldvari², Ekaterina Alexeeva³, Nuray Aktay Ayaz⁴, Grant Schulert⁵, Seza Ozen⁶, Artem Popov⁷, Athimalaipet V Ramanan⁸, Christiaan Scott⁹, Betul Sozeri¹⁰, Elena Zholobova¹¹, Sudhanshu Chakraborty¹², Xuan Zhu¹³, Ruvie Martin¹³, Sarah Whelan¹⁴, Sharonjeet Kaur¹⁵, Luminita Pricop¹³, Daniel J Lovell¹⁶, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder und Jugendrheumatologie, Rheumatology, Hamburg, Germany, ³National Scientific and Practical Center of Children's Health, Rheumatology, Moscow, Russia, ⁴Department of Pediatric Rheumatology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Hacettepe University Medical Faculty, Ankara, Turkey, ⁷Ural State Medical University Ekaterinburg, Sverdlovsk, Russia, ⁸Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, ⁹Department of Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa, ¹⁰Division of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey, ¹¹First Moscow State Medical University, n.a. I.M.Sechenov, Moscow, Russia, ¹²IQVIA, Durrham, NC, ¹³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Ireland Ltd, Dublin, Ireland, ¹⁵Novartis Pharma AG, Basel, Switzerland, ¹⁶UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, ¹⁷Università di Genova, Genova, Italy, ¹⁸IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy
Background/Purpose: Secukinumab has demonstrated efficacy and safety in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) categories of juvenile idiopathic arthritis (JIA) for…
Abstract Number: 0524 • ACR Convergence 2023
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Nigil Haroon¹, Zeynep Baskurt², Tina Chim³, Robert Inman⁴, Diana Paez⁵, Thomas Kumke⁶, Rachel Tham⁷, Mindy Kim⁸, Irene van der Horst-Bruinsma⁹ and Lianne Gensler¹⁰, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ²Department of Biostatistics, University Health Network, Toronto, ON, Canada, ³University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine/Rheumatology, San Francisco, CA, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Atlanta, GA, ⁹Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands, ¹⁰University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting more than a third of patients. However, long-term interventional…
Abstract Number: 0842 • ACR Convergence 2023
Low Rate of Switching from Nr-axSpA to r-axSpA After 10 Years of Follow up in Early Axialspondyloarthritis. Data from DESIR Cohort
Anna Molto¹, Clementina López Medina², Manouk de Hooge³, Miranda Van Lunteren⁴, Alexandre Sepriano⁵, Sofia Ramiro⁶ and Maxime Dougados⁷, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ³Ghent University Hospital, Hesperange, Luxembourg, ⁴Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁵Leiden University Medical Centre, Portela Loures, Portugal, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France
Background/Purpose: The objective of this analysis was to evaluate the proportion of patients switching from non-radiographic axSpA (nr-axSpA) toradiographic axSpA (r-axSpA) after 10 years of…
Abstract Number: 1392 • ACR Convergence 2023
Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project
Denis Poddubnyy¹, Marc Kämmerer², Marcus Kremers³, Berit Schoppen³, Charlotte Arens³, Annette Wiedon⁴, Imke Redeker⁵ and Xenofon Baraliakos⁶, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²VISUS Health IT GmbH, Bochum, Germany, ³MedEcon Telemedizin GmbH / MedEcon Ruhr GmbH, Bochum, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Ruhr Universität Bochum, Bochum, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is often diagnosed late, while there is also a problem of over- and misdiagnosis in patients with chronic back pain. Imaging,…
Abstract Number: 1776 • ACR Convergence 2023
Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression
Shaghayegh Foroozan¹ and Nigil Haroon², ¹University Health Network/University of Toronto, Toronto, ON, Canada, ²University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of…
Abstract Number: 1892 • ACR Convergence 2023
Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study
De Meester Liesbet¹, Gaelle Varkas², Manouk de Hooge³, Ann-Sophie De Craemer⁴, Nele Herregods⁵, Lennart Jans⁵, Philippe Carron⁶, Dirk Elewaut⁷ and Filip Van den Bosch⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Ghent University Hospital, Hesperange, Luxembourg, ⁴Ghent University Hospital, Gent, Belgium, ⁵Department of Radiology, Ghent University Hospital, Ghent, Belgium, ⁶UZ Gent, Gent, Belgium, ⁷Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁸Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Sacroiliac bone marrow oedema (BMO) on MRI, immediately after childbirth, has been observed in a large proportion of postpartum women and appears to be…

« Previous Page
1
…
7
8
9
10
11
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].